AIMS/HYPOTHESIS: Decreased sensing of the innate immune system may lead to chronic activation of the inflammatory cascade. We hypothesised that mannan-binding lectin (MBL) deficiency may confer risk of obesity and insulin resistance. MATERIALS AND METHODS: We performed a cross-sectional study of MBL protein concentration (n=434) and MBL2 gene mutations (exon 1) (n=759) in association with obesity, markers of inflammation and insulin action (euglycaemic clamp, n=113), and a longitudinal study of MBL protein before and after weight loss in obese patients (n=10). We also studied the effects of MBL in vitro in muscle cells and circulating MBL-A (mouse equivalent of human MBL) in a mouse model. RESULTS: Among 434 consecutive non-diabetic men, the age-adjusted serum MBL concentration was lower in obese subjects than in lean subjects (median: 959 microg/ml [interquartile range: 116.8-2,044 microg/ml] vs 1,365 [467-2,513] microg/ml; p=0.01) and was accompanied by increased serum inflammatory markers. Insulin action correlated significantly with serum MBL (r=0.49, p<0.0001). Serum MBL concentration increased by a median of 110.2% after weight loss. The change in serum concentration of MBL was positively associated with the increase in insulin sensitivity (r=0.713, p=0.021). At least one MBL2 gene mutation was present in 48.2% of obese vs 39.3% of non-obese subjects (p=0.037). The plasma concentration of MBL-A was lower in insulin-resistant obese ob/ob mice, as was the glucose/insulin ratio. Incubation of rat soleus muscle with human MBL markedly increased fatty acid oxidation. CONCLUSIONS/ INTERPRETATION: These findings suggest that MBL, previously thought only to be involved in inflammation and immune system function, affects metabolic pathways.
AIMS/HYPOTHESIS: Decreased sensing of the innate immune system may lead to chronic activation of the inflammatory cascade. We hypothesised that mannan-binding lectin (MBL) deficiency may confer risk of obesity and insulin resistance. MATERIALS AND METHODS: We performed a cross-sectional study of MBL protein concentration (n=434) and MBL2 gene mutations (exon 1) (n=759) in association with obesity, markers of inflammation and insulin action (euglycaemic clamp, n=113), and a longitudinal study of MBL protein before and after weight loss in obesepatients (n=10). We also studied the effects of MBL in vitro in muscle cells and circulating MBL-A (mouse equivalent of humanMBL) in a mouse model. RESULTS: Among 434 consecutive non-diabeticmen, the age-adjusted serum MBL concentration was lower in obese subjects than in lean subjects (median: 959 microg/ml [interquartile range: 116.8-2,044 microg/ml] vs 1,365 [467-2,513] microg/ml; p=0.01) and was accompanied by increased serum inflammatory markers. Insulin action correlated significantly with serum MBL (r=0.49, p<0.0001). Serum MBL concentration increased by a median of 110.2% after weight loss. The change in serum concentration of MBL was positively associated with the increase in insulin sensitivity (r=0.713, p=0.021). At least one MBL2 gene mutation was present in 48.2% of obese vs 39.3% of non-obese subjects (p=0.037). The plasma concentration of MBL-A was lower in insulin-resistant obese ob/ob mice, as was the glucose/insulin ratio. Incubation of rat soleus muscle with humanMBL markedly increased fatty acid oxidation. CONCLUSIONS/ INTERPRETATION: These findings suggest that MBL, previously thought only to be involved in inflammation and immune system function, affects metabolic pathways.
Authors: M Saraheimo; C Forsblom; T K Hansen; A-M Teppo; J Fagerudd; K Pettersson-Fernholm; S Thiel; L Tarnow; P Ebeling; A Flyvbjerg; P-H Groop Journal: Diabetologia Date: 2004-12-23 Impact factor: 10.122
Authors: J M Fernandez-Real; M Vayreda; C Richart; C Gutierrez; M Broch; J Vendrell; W Ricart Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: A Koch; M Melbye; P Sørensen; P Homøe; H O Madsen; K Mølbak; C H Hansen; L H Andersen; G W Hahn; P Garred Journal: JAMA Date: 2001-03-14 Impact factor: 56.272
Authors: M I Schmidt; B B Duncan; A R Sharrett; G Lindberg; P J Savage; S Offenbacher; M I Azambuja; R P Tracy; G Heiss Journal: Lancet Date: 1999-05-15 Impact factor: 79.321
Authors: Federico Soriguer; Gemma Rojo-Martínez; M Carmen Dobarganes; José M García Almeida; Isabel Esteva; Manuela Beltrán; M Soledad Ruiz De Adana; Francisco Tinahones; Juan M Gómez-Zumaquero; Eduardo García-Fuentes; Stella González-Romero Journal: Am J Clin Nutr Date: 2003-12 Impact factor: 7.045
Authors: Andrey S Glotov; Evgeny S Tiys; Elena S Vashukova; Vladimir S Pakin; Pavel S Demenkov; Olga V Saik; Timofey V Ivanisenko; Olga N Arzhanova; Elena V Mozgovaya; Marina S Zainulina; Nikolay A Kolchanov; Vladislav S Baranov; Vladimir A Ivanisenko Journal: BMC Syst Biol Date: 2015-04-15
Authors: Yunhua L Muller; Robert L Hanson; Li Bian; Janel Mack; Xiaolian Shi; Ruth Pakyz; Alan R Shuldiner; William C Knowler; Clifton Bogardus; Leslie J Baier Journal: Diabetes Date: 2010-06-03 Impact factor: 9.461
Authors: Christine von Toerne; Cornelia Huth; Tonia de Las Heras Gala; Florian Kronenberg; Christian Herder; Wolfgang Koenig; Christa Meisinger; Wolfgang Rathmann; Melanie Waldenberger; Michael Roden; Annette Peters; Barbara Thorand; Stefanie M Hauck Journal: Diabetologia Date: 2016-06-25 Impact factor: 10.122
Authors: L Varga; G Széplaki; J Laki; A Kocsis; K Kristóf; P Gál; Z Bajtay; J Wieslander; M R Daha; P Garred; H O Madsen; G Füst; H Farkas Journal: Clin Exp Immunol Date: 2008-05-05 Impact factor: 4.330
Authors: Rebecca Ilyas; Russell Wallis; Elizabeth J Soilleux; Paul Townsend; Daniel Zehnder; Bee K Tan; Robert B Sim; Hendrik Lehnert; Harpal S Randeva; Daniel A Mitchell Journal: Immunobiology Date: 2010-07-01 Impact factor: 3.144
Authors: Olga V Arkova; Mikhail P Ponomarenko; Dmitry A Rasskazov; Irina A Drachkova; Tatjana V Arshinova; Petr M Ponomarenko; Ludmila K Savinkova; Nikolay A Kolchanov Journal: BMC Genomics Date: 2015-12-16 Impact factor: 3.969